IGC Pharma, Inc. (IGC)

Market Cap	39.08M
Revenue (ttm)	1.33M
Net Income (ttm)	-6.34M
Shares Out	90.91M
EPS (ttm)	-0.08
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	304,198
Open	0.4179
Previous Close	0.4230
Day's Range	0.4151 - 0.4380
52-Week Range	0.2525 - 0.4985
Beta	1.08
Analysts	Strong Buy
Price Target	4.00 (+830.45%)
Earnings Date	Nov 11, 2025

About IGC

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops treatments for Alzheimer’s disease in the United States and Colombia. The company’s lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer’s. Its pre-clinical stage product candidate includes TGR-63, IGC-M3, and LMP to treat Alzheimer’s disease; IGC-1C for the treatment of metabolic disorders and Alzheimer’s disease; and IGC-1A to treat metabolic disorders. The company was formerly known as India Globalization Capi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 70
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: IGC
• Website: https://igcpharma.com

Financial Performance

In 2024, IGC Pharma's revenue was $1.27 million, a decrease of -5.50% compared to the previous year's $1.35 million. Losses were -$7.12 million, -45.22% less than in 2023.

Analyst Summary

According to 2 analysts, the average rating for IGC stock is "Strong Buy." The 12-month stock price target is $4.0, which is an increase of 830.45% from the latest price.

Price Target

$4.0

(830.45% upside)

Analyst Consensus: Strong Buy